Cargando…

The global crisis of drug-resistant tuberculosis and leadership of China and the BRICS : challenges and opportunities : summary of a joint workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences /

Multidrug-resistant tuberculosis (TB) is caused by bacteria resistant to isoniazid and rifampicin, the two most effective first-line anti-TB drugs, originally developed and introduced in the 1950 and 1960s. Since 2008, the Forum on Drug Discovery, Development, and Translation of the Institute of Med...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autores principales: Olson, Steve, 1956- (Autor), English, Rebecca A. (Autor), Claiborne, Anne B. (Autor)
Autores Corporativos: Institute of Medicine (U.S.) (sponsoring body.), Zhongguo ke xue yuan. Wei sheng wu yan jiu suo (sponsoring body.), Global Crisis of Drug-Resistant Tuberculosis and Leadership of the BRICS Countries : Challenges and Opportunities (Workshop)
Formato: Electrónico Congresos, conferencias eBook
Idioma:Inglés
Publicado: Washington, D.C. : The National Academies Press, [2014]
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000 i 4500
001 EBOOKCENTRAL_ocn870331213
003 OCoLC
005 20240329122006.0
006 m o d
007 cr un|||||||||
008 140516s2014 dcua obt 100 0 eng
040 |a NLM  |b eng  |e rda  |e pn  |c NLM  |d COO  |d LTSCA  |d YDXCP  |d E7B  |d VT2  |d COP  |d MMU  |d UCNAP  |d N$T  |d EBLCP  |d DEBSZ  |d OCLCO  |d D6H  |d OCLCA  |d OCLCQ  |d OCLCO  |d COCUF  |d MOR  |d ZCU  |d MERUC  |d OCLCQ  |d OCLCA  |d OCLCO  |d OCLCA  |d U3W  |d OCLCA  |d OCLCF  |d STF  |d VTS  |d EZ9  |d ICG  |d OCLCQ  |d OCLCO  |d NLM  |d LVT  |d TKN  |d DKC  |d OCLCO  |d AU@  |d OCLCQ  |d OCLCO  |d OCLCQ  |d K6U  |d OCLCA  |d UKAHL  |d OCLCO  |d OCLCQ  |d OCL  |d OCLCO  |d OCLCL 
016 7 |a 101633144  |2 DNLM 
019 |a 871260167  |a 923287859  |a 971083063  |a 1021272863  |a 1061003944  |a 1061062305  |a 1077380361  |a 1081271153  |a 1156332799  |a 1228550393  |a 1249253375 
020 |a 9780309285964 
020 |a 0309285968 
020 |a 9780309285971 
020 |a 0309285976 
029 0 |a NLM  |b 101633144 
029 1 |a DEBBG  |b BV042793566 
029 1 |a DEBBG  |b BV044185084 
029 1 |a DEBSZ  |b 446490083 
029 1 |a DEBSZ  |b 452580358 
029 1 |a GBVCP  |b 814956696 
035 |a (OCoLC)870331213  |z (OCoLC)871260167  |z (OCoLC)923287859  |z (OCoLC)971083063  |z (OCoLC)1021272863  |z (OCoLC)1061003944  |z (OCoLC)1061062305  |z (OCoLC)1077380361  |z (OCoLC)1081271153  |z (OCoLC)1156332799  |z (OCoLC)1228550393  |z (OCoLC)1249253375 
042 |a pcc 
043 |a a-cc--- 
050 4 |a RC311.1  |b .G56 2014 
060 0 0 |a 2014 I-005 
060 0 0 |a WF 200 
072 7 |a POL  |x 027000  |2 bisacsh 
072 7 |a POL  |x 019000  |2 bisacsh 
082 0 4 |a 362.19699/5  |2 23 
049 |a UAMI 
100 1 |a Olson, Steve,  |d 1956-  |e author. 
245 1 4 |a The global crisis of drug-resistant tuberculosis and leadership of China and the BRICS :  |b challenges and opportunities : summary of a joint workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences /  |c Steve Olson, Rebecca A. English, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies. 
264 1 |a Washington, D.C. :  |b The National Academies Press,  |c [2014] 
300 |a 1 online resource (1 PDF file (xxi, 195 pages)) :  |b illustrations 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
500 |a Title from PDF title page. 
504 |a Includes bibliographical references. 
520 3 |a Multidrug-resistant tuberculosis (TB) is caused by bacteria resistant to isoniazid and rifampicin, the two most effective first-line anti-TB drugs, originally developed and introduced in the 1950 and 1960s. Since 2008, the Forum on Drug Discovery, Development, and Translation of the Institute of Medicine has hosted or co-hosted six domestic and international workshops addressing the global crisis of drug-resistant TB, with special attention to the BRICS countries - Brazil, Russia, India, China, and South Africa. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS is the summary of a workshop convened to address the current status of drug-resistant TB globally and in China. This report considers lessons learned from high burden countries; highlights global challenges to controlling the spread of drug-resistant strains; and discusses innovative strategies to advance and harmonize local and international efforts to prevent and treat drug-resistant TB. Additionally, the report examines the problem of MDR TB and emergent TB strains that are potentially untreatable with drugs available and considers the critical leadership role of the BRICS countries in addressing the threats and opportunities in drug-resistant TB. 
536 |a This activity was supported by contracts between the National Academy of Sciences and Department of Health and Human Services (HHSN26300023 [Under Base #HHSN263201200074I] and Contract No. N01-OD-4-2139 TO #276; HHSF22301026T [Under Base #HHSF223200810020I]), AbbVie Inc., American Diabetes Association, American Society for Microbiology, Amgen Inc., Association of American Medical Colleges, AstraZeneca, Bristol-Myers Squibb, Burroughs Wellcome Fund, CDC Foundation, Celtic Therapeutics, LLLP, Critical Path Institute, Doris Duke Charitable Foundation, Eli Lilly & Co. Foundation, Eli Lilly and Company, FasterCures, Fondation Merieux, Friends of Cancer Research, GlaxoSmithKline, Johnson & Johnson, March of Dimes Foundation, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., and Sanofi. The views presented in this publication do not necessarily reflect the views of the organizations or agencies that provided support for the activity. 
588 0 |a Version viewed June 30, 2014. 
505 0 |a The challenges and opportunities for the BRICS countries to lead -- Catching up with the microbe -- Drug-resistant TB in China -- Experiences with MDR TB in other countries -- Drug-resistant tuberculosis in pediatric populations -- Global perspectives on transmission and infection control -- Rapid diagnostic technologies : status and limitations -- Addressing diagnosis and treatment across the spectrum of drug resistance -- Developing and strengthening the drug supply chain for drug-resistant TB -- Embracing a new vision for research -- What will be required to achive zero deaths from TB? -- Creating an evidence-based blueprint for action. 
590 |a ProQuest Ebook Central  |b Ebook Central Academic Complete 
590 |a eBooks on EBSCOhost  |b EBSCO eBook Subscription Academic Collection - Worldwide 
650 0 |a Multidrug-resistant tuberculosis  |v Congresses. 
650 0 |a Multidrug-resistant tuberculosis  |x Prevention  |v Congresses. 
650 0 |a Tuberculosis  |v Congresses. 
650 0 |a Drug resistance  |v Congresses. 
650 0 |a Multidrug-resistant tuberculosis. 
650 0 |a Antitubercular agents. 
650 0 |a World health. 
650 0 |a International cooperation. 
650 1 2 |a Tuberculosis, Multidrug-Resistant 
650 2 2 |a Antitubercular Agents 
650 2 2 |a Global Health 
650 2 2 |a International Cooperation 
651 2 |a China 
650 6 |a Tuberculose multirésistante  |v Congrès. 
650 6 |a Tuberculose  |v Congrès. 
650 6 |a Résistance aux médicaments  |v Congrès. 
650 6 |a Tuberculose multirésistante. 
650 6 |a Antituberculeux. 
650 6 |a Santé mondiale. 
650 6 |a Coopération internationale. 
650 7 |a POLITICAL SCIENCE  |x Public Policy  |x Social Security.  |2 bisacsh 
650 7 |a POLITICAL SCIENCE  |x Public Policy  |x Social Services & Welfare.  |2 bisacsh 
650 7 |a World health  |2 fast 
650 7 |a International cooperation  |2 fast 
650 7 |a Antitubercular agents  |2 fast 
650 7 |a Drug resistance  |2 fast 
650 7 |a Multidrug-resistant tuberculosis  |2 fast 
650 7 |a Tuberculosis  |2 fast 
655 2 |a Congress 
655 7 |a proceedings (reports)  |2 aat 
655 7 |a Conference papers and proceedings  |2 fast 
655 7 |a Conference papers and proceedings.  |2 lcgft 
655 7 |a Actes de congrès.  |2 rvmgf 
700 1 |a English, Rebecca A.,  |e author. 
700 1 |a Claiborne, Anne B.,  |e author. 
710 2 |a Institute of Medicine (U.S.).  |b Forum on Drug Discovery, Development, and Translation,  |e issuing body. 
710 2 |a Institute of Medicine (U.S.),  |e sponsoring body. 
710 2 |a Zhongguo ke xue yuan.  |b Wei sheng wu yan jiu suo,  |e sponsoring body. 
711 2 |a Global Crisis of Drug-Resistant Tuberculosis and Leadership of the BRICS Countries : Challenges and Opportunities (Workshop)  |d (2013 :  |c Beijing, China) 
758 |i has work:  |a The global crisis of drug-resistant tuberculosis and leadership of China and the BRICS (Text)  |1 https://id.oclc.org/worldcat/entity/E39PCGdjBGJjtrxyhPdjPMWwwd  |4 https://id.oclc.org/worldcat/ontology/hasWork 
776 0 8 |i Print version:  |a Global Crisis of Drug-Resistant Tuberculosis and Leadership of the BRICS Countries : Challenges and Opportunities (Workshop) (2013 : Beijing, China).  |t Global crisis of drug-resistant tuberculosis and leadership of China and the BRICS.  |d Washington, D.C. : National Academies Press, [2014]  |z 9780309285964 
856 4 0 |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=3379093  |z Texto completo 
938 |a Askews and Holts Library Services  |b ASKH  |n AH36561400 
938 |a Askews and Holts Library Services  |b ASKH  |n AH36617758 
938 |a ProQuest Ebook Central  |b EBLB  |n EBL3379093 
938 |a ebrary  |b EBRY  |n ebr10863741 
938 |a EBSCOhost  |b EBSC  |n 867773 
938 |a YBP Library Services  |b YANK  |n 11575900 
938 |a YBP Library Services  |b YANK  |n 11864833 
994 |a 92  |b IZTAP